Skip to content
DataLookout
Menu

DISCOVERYNCT07390643

The DISCOVER Study

StatusActive, Not Recruiting
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 4 words Show 6 more changesShow less
    • Trial status changed: Not Yet Recruiting → Active, Not Recruiting
    • Primary completion date changed from estimate of Jan 31, 2027 to Sep 24, 2026
    • Study completion pushed from Jan 31, 2028 to Oct 31, 2028
    • Start date changed from estimate of Jul 2026 to Feb 11, 2026
    • Secondary endpoints: details revised at 1 of 5 entries
    • Site contact updated
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Multi-cancer Early Detection (MCED) Positive Cancer Type
Timeframe: MCED testing will be performed at enrollment, with diagnostic resolution and cancer type determination expected within 12 months.
Multi-cancer Early Detection (MCED) Positive Cancer Incidence
Timeframe: MCED testing will be performed at enrollment, with diagnostic resolution and cancer type determination expected within 12 months.
Multi-cancer Early Detection (MCED) Positive Cancer Stage
Timeframe: MCED testing will be performed at enrollment, with diagnostic resolution and cancer type determination expected within 12 months.
Multi-cancer Early Detection (MCED) Undetected Cancer Type
Timeframe: MCED testing will be performed at enrollment, with diagnostic resolution and cancer type determination expected within 12 months.
Multi-cancer Early Detection (MCED) Undetected Cancer Incidence
Timeframe: MCED testing will be performed at enrollment, with diagnostic resolution and cancer type determination expected within 12 months.
Multi-cancer Early Detection (MCED) Undetected Cancer Stage
Timeframe: MCED testing will be performed at enrollment, with diagnostic resolution and cancer type determination expected within 12 months.

Secondary (5)

Positive Predictive Value (PPV) of Multi-cancer Early Detection (MCED)
Number of Additional Tests
Types of Additional Tests
Tissue of Origin Correct Prediction Rate
Qualitative Provider Assessment of MCED Test Utility

Arms and interventions

Galleri MCED TestExperimental

Enrolled participants will complete: * Baseline visit with blood draw and questionnaires * Return of test results: * For a positive result, diagnostic work-up could include clinic visits, biopsy, surgery, imaging assessments such as ultrasound, Computed Tomography (CT) scans, or Magnetic Resonance Imaging (MRI) scans. If standard, diagnostic work-up is positive or negative for cancer, follow up will be at the discretion of the principal investigator. * For a negative MCED blood test with standard, diagnostic work-up that is negative, follow-up will be at the discretion of the principal investigator. * Online post-test questionnaire * Online post-diagnostic questionnaire * Follow up will be up to 24 months

Devices: GRAIL Galleri MCED test

Sites

1 site in 1 country

  • Dana-Farber Cancer InstituteBoston, Massachusetts, United States